Table 2.
General characteristics of prognostic predictors for GIACs.
| Tumor type | Alternative splicing | Formula | Hazard ratios (95% CI) | ROC | C-index |
|---|---|---|---|---|---|
| Esophageal adenocarcinoma | AA | “U2AF1L4-49,280-AA” * 0.02105 + “TICRR-32428-AA” * (−0.01414) + “RSRC2-24968-AA” * (−0.02971) + “PREPL-53439-AA” * 0.02192 + “PPIL2-61247-AA” * 0.03579 + “FAM135A-76,637-AA” * 0.03004 + “CDV3-66839-AA” * 0.04154 + “ABCB7-89517-AA” * (−0.02951) | 4.492 (2.333–8.647) | 0.897 | 0.798 |
| AD | “ZNF384-19927-AD” * (−0.05812) + “RPP14-65434-AD” * (−0.03077) + “PQBP1-89028-AD” * 0.02678 + “MFSD11-43690-AD” * 0.02587 + “COX6C-84,682-AD” * 0.04491 | 4.490 (2.362–8.534) | 0.745 | 0.800 | |
| AP | “ZNF623-85469-AP” * (−0.04535) + “KIAA0513-37876-AP” * 0.01779 + “FAM19A5-62,732-AP” * 0.04833 + “ALDH6A1-28,367-AP” * 0.03834 | 4.366 (2.276–8.376) | 0.817 | 0.794 | |
| AT | “TRIM4-80864-AT” * (−2.67e-02) + “RNASEH2B-25,927-AT” * (−2.61e + 02) + “RNASEH2B-25,926-AT” * -2.61e + 02 + “MCPH1-82574-AT” * 1.72e-02 + “ARL6-65732-AT” * 4.29e-02 + “AHI1-77886-AT” * (−2.30e-02) | 4.143 (2.219–7.734) | 0.831 | 0.778 | |
| ES | “TNC-87345-ES” * 0.03180 + “PML-31651-ES” * -0.01033 + “NBPF15-91080-ES” * (0.07165 + “MYL6-22384-ES” * (−0.04943) + “MRPL43-12857-ES” * -0.03976 + “IRF9-117161-ES” * (−0.01943) | 4.235 (2.242–8.001) | 0.904 | 0.843 | |
| ME | “SDR39U1-27,012-ME” * (−0.01054) + “KLHL2-71038-ME” * (−0.02045) + “CMC2-37707-ME” * 0.02191 | 3.522 (1.858–6.674) | 0.864 | 0.690 | |
| RI | “ZNF131-71926-RI” * (−0.03666) + “SLC52A3-58,464-RI” * 0.03577 + “PPARGC1B-74,051-RI” 0.01544 + “PCGF3-68404-RI” * 0.02876 + “MDK-15570-RI” * 0.05833 + “MAF-37687-RI” * 0.05197 + “FAM9C-88,504-RI” * (−0.02045) | 5.643 (2.97–10.72) | 0.827 | 0.795 | |
| Stomach adenocarcinoma | AA | “RPLP0-24727-AA” * (−0.01196) + “NAT6-64990-AA” * 0.01181 + “MRVI1-14373-AA” * 0.00731 + “LMO7-26065-AA” * 0.01256 + “BDKRB2-29192-AA” * (−0.00776) | 2.299 (1.649–3.205) | 0.718 | 0.639 |
| AD | “YIPF2-47605-AD” * (−0.01345) + “SPHK2-50793-AD” * 0.01230 + “SENP1-21411-AD” * 0.00842 + “PGAP2-14004-AD” * (−0.01311) + “NFATC1-46241-AD” * 0.00822 + “CCDC51-64653-AD” * (−0.00669) | 2.048 (1.468–2.858) | 0.773 | 0.630 | |
| AP | “RCAN1-60494-AP” * 0.01222 + “PLCD1-64009-AP” * 0.00891 + “LTBP1-53179-AP” * (−0.00835) + “FAM65B-75,537-AP” * 0.02503 + “ABL2-9101-AP” * (−0.00857) | 2.493 (1.790–3.472) | 0.646 | 0.665 | |
| AT | “ZNF846-47399-AT” *7.44e-03 + “ZFYVE28-68559-AT” (−2.01e-02) + “STEAP4-80362-AT” * (−5.58e + 01) + “STEAP4-80361-AT” * (−5.58e + 01) + “KIF1B-602-AT” *5.58e + 01 + “KIF1B-601-AT” *5.58e + 01 + “CXCL12-11344-AT” * (−1.50e-02) + “CLDN11-67617-AT” * (−1.41e-03) + “ABCB5-78909-AT” *1.67e-02 + | 2.647 (1.893–3.700) | 0.773 | 0.658 | |
| ES | “UBXN11-1263-ES” * (−0.02472) + “TMEM230-58637-ES” * 0.01826 + “SRSF3-75985-ES” * 0.01602 + “SORBS1-12641-ES” * 0.00880 + “P4HA2-73,263-ES” * (−0.01086) + “CREM-11245-ES” * (−0.01342) | 2.461 (1.765–3.432) | 0.801 | 0.679 | |
| ME | “N4BP2L1-25,590-ME” * (−0.00781) + “KDM6A-98,323-ME” * (−0.00884) + “FYN-77273-ME” * 0.00995 + “CCDC53-106010-ME” * 0.00973 | 1.491 (1.070–2.077) | 0.631 | 0.590 | |
| RI | “TREX1-64682-RI” * 0.01573 + “SRSF7-53276-RI” * (−0.02285) + “RPS15-46490-RI” * (−0.01897) + “LDHA-14642-RI” * 0.00548 + “BICD2-86883-RI” * (−0.00777) + “ALS2CL-64,462-RI” * 0.00983 | 2.842 (2.036–3.968) | 0.800 | 0.656 | |
| Colon adenocarcinoma | AA | “RASSF7-13691-AA” * 0.02897 + “PTGR1-87219-AA” * 0.02644 + “FAM173A-32,964-AA” * 0.02221 + “DPP3-17040-AA” * (−0.01817) + “CDV3-66842-AA” * 0.02860 | 3.983 (2.623–6.048) | 0.737 | 0.723 |
| AD | “RNF14-73855-AD” * 0.01562 + “IP6K2-64,759-AD” * 0.01261 + “HPS4-61506-AD” * 0.02158 + “HDGF-8323-AD” * 0.01968 + “ANKRD46-84712-AD” * 0.02147 + “ADPGK-31594-AD” * 0.01645 | 3.224 (2.126–4.888) | 0.680 | 0.676 | |
| AP | “TUBB3-38167-AP” * (−0.01030) + “RAB3IP-23,345-AP” * (−0.03643) + “MAZ-35938-AP” * 0.02384 + “FADS2-16289-AP” * 0.01878 + “ENO2-20011-AP” * 0.00736 | 3.436 (2.268–5.206) | 0.710 | 0.681 | |
| AT | “ZNF765–51718-AT” * (−4.08e-02) + “UPK3B-80,182-AT” * 2.05e-02 + “RASEF-86677-AT” * 1.37e + 02 + “RASEF-86676-AT” * 1.37e + 02 + “NRG4-31911-AT” * 3.04e-02 + “AIG1-77972-AT” * (−1.62e-02) | 3.262 (2.147–4.958) | 0.752 | 0.720 | |
| ES | “VTI1B-28,083-ES” * (−0.01045) + “STRN3-27098-ES” * (−0.02262) + “RHOC-4236-ES” * 0.01902 + “PRMT1-51042-ES” * 0.01818 + “PLEKHM2-767-ES” * 0.01972 + “DMWD-50528-ES” * 0.02082 + “D2HGDH-58,423-ES” * 0.02800 | 3.013 (1.981–4.582) | 0.769 | 0.730 | |
| ME | “CNOT10-63822-ME” * 0.0236 | 1.479 (0.976–2.242) | 0.585 | 0.561 | |
| RI | “ZNF226-50290-RI” * 0.01131 + “NPIPA5-34148-RI” * 0.02178 + “ELP5-38889-RI” * (−0.03011) + “ALS2CL-64,463-RI” * 0.01968 | 2.711 (1.788–4.110) | 0.696 | 0.679 | |
| Rectum adenocarcinoma | AA | “ZNF467-82205-AA” * −0.01766 + “RNPC3-3907-AA” * −0.03513 + “GGT1-61440-AA” * −0.01812 + “BTN3A1-75,660-AA” * −0.01810 | 4.321 (1.902–9.819) | 0.728 | 0.766 |
| AD | “OSBPL9-2975-AD” * 0.01167 + “METTL23-43637-AD” * 0.03522 + “BCS1L-57,522-AD” * (−0.02063) | 3.177 (1.401–7.205) | 0.794 | 0.718 | |
| AP | “TADA2B-68,732-AP” * (−0.01496) + “PTCH1-86955-AP” * 0.02493 + “DAB2IP-87,442-AP” * 0.02235 | 4.897 (2.162–11.09) | 0.860 | 0.694 | |
| AT | “PUS10-53676-AT” * 0.0635 + “NOTCH2NL-4437-AT” 0.0541 | 4.592 (2.015–10.46) | 0.912 | 0.738 | |
| ES | “SPAG9-42496-ES” * −0.0325 + “SERPINA1-29134-ES” * 0.0455 + “PHB2-20048-ES” * (−0.0223) + “FGFR1OP2-20,856-ES” * 0.0529 | 8.372 (3.577–19.6) | 0.832 | 0.797 | |
| ME | “RBMS2-22465-ME” * (−0.01912) | 1.742 (0.769–3.947) | 0.574 | 0.591 | |
| RI | “ZNF692-10557-RI” * −0.05799 + “WDR33-55246-RI” *0.03283 + “TMEM91-50046-RI” * 0.00968 + “SIDT2-18886-RI” * 0.03883 + “EXOSC9-70501-RI” * (−0.02814) + “ADARB1-60863-RI” * (−0.03719) | 8.766 (3.841–20) | 0.937 | 0.767 |
Hazard ratios were estimated between high- and low-risk groups.